CoChat
Sign Up
Cited by 29MicroRNA in disease regulationCancer-related molecular mechanisms researchBladder and Urothelial Cancer Treatments

Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection

Open access
TAO, JUN, YANG, XIAO, LI, PENGCHAO, WEI, JIFU, DENG, XIAHENG, CHENG, YIDONG, QIN, CHAO, JU, XIAOBING +5 more·2015·Molecular Medicine Reports
DOI 10.3892/mmr.2015.4257PMC PMC4626156
Open this paper in CoChat — free accountOpen PDF

Abstract

The involvement of circulating microRNAs (miRNAs) in cancer and their potential as diagnostic and prognostic biomarkers are becoming increasingly known. However, the significance of circulating miRNAs in upper tract urothelial carcinoma (UTUC) has remained to be investigated. The present study performed a genome‑wide serum miRNA analysis using a deep sequencing platform for initial screening. Subsequently, serum samples of 46 UTUC patients and 30 cancer‑free individuals with hematuria were subjected to a quantitative reverse‑transcription polymerase chain reaction analysis. The expression of thirteen miRNAs (miR‑664a‑3p, miR‑423‑5p, miR‑431‑5p, miR‑191‑5p, miR‑92a‑3p, miR‑22‑3p, miR‑26a‑5p, miR‑33b‑3p, miR‑16‑5p, let‑7a‑5p, let‑7b‑5p, let‑7f‑5p and let‑7c) was significantly different in serum from UTUC patients compared with that in control samples. Receiver operator characteristic analysis showed that 10 miRNAs (miR‑664a‑3p, miR‑431‑5p, miR‑423‑5p, miR‑191‑5p, miR‑33b‑3p, miR‑26a‑5p, miR‑22‑3p, miR‑16‑5p, let‑7b‑5p and let‑7c) had the potential to distinguish individuals with UTUC from the controls (areas under the curve >0.8). The present study provided the first evidence for the potential use of circulating miRNAs as biomarkers for UTUC diagnosis, which remains to be verified by further studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mmr.2015.4257

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Decreased level of circulating miR-33b-3p was detected in patients with upper tract urothelial carcinoma in comparison with normal control group.

    “In addition, decreased level of circulating miR-33b-3p was detected in patients with upper tract urothelial carcinoma in comparison with normal control group (36), supporting the tumor suppressive role of miR-33b-3p.”

    From miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer (2021) · cites this paper as [36]

    The Discussion (page unavailable) states the opposite: serum miR-33b expression was enhanced in UTUC cases. It contrasts this with lower plasma miR-33b in bladder cancer cases, not UTUC cases. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 50

  1. [1]Hall MC Womack S Sagalowsky AI Carmody T Erickstad MD Roehrborn CG Prognostic factors, recurrence and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients Urology 52 594 601 1998 10.1016/S0090-4295(98)00295-7 9763077 · DOI
  2. [2]Munoz JJ Ellison LM Upper tract urothelial neoplasms: Incidence and survival during the last 2 decades J Urol 164 1523 1525 2000 10.1016/S0022-5347(05)67019-X 11025695 · DOI
  3. [3]Rouprêt M Zigeuner R Palou J Boehle A Kaasinen E Sylvester R Babjuk M Oosterlinck W European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update Eur Urol 59 584 594 2011 10.1016/j.eururo.2010.12.042 21269756 · DOI
  4. [4]Krabbe LM Lotan Y Bagrodia A Gayed BA Darwish OM Youssef RF Bolenz C Sagalowsky AI Raj GV Shariat SF Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract is there evidence for discordant biology? J Urol 191 926 931 2014 10.1016/j.juro.2013.09.031 24060642 · DOI
  5. [5]Hautmann RE de Petriconi RC Pfeiffer C Volkmer BG Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: Long term results in 1100 patients Eur Urol 61 1039 1047 2012 10.1016/j.eururo.2012.02.028 22381169 · DOI
  6. [6]Margulis V Shariat SF Matin SF Kamat AM Zigeuner R Kikuchi E Lotan Y Weizer A Raman JD The Upper Tract Urothelial Carcinoma Collaboration Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration Cancer 115 1224 1233 2009 10.1002/cncr.24135 19156917 · DOI
  7. [7]Winter J Jung S Keller S Gregory RI Diederichs S Many roads to maturity: microRNA biogenesis pathways and their regulation Nat Cell Biol 11 228 234 2009 10.1038/ncb0309-228 19255566 · DOI
  8. [8]Lin S Gregory RI MicroRNA biogenesis pathways in cancer Nat Rev Cancer 15 321 333 2015 10.1038/nrc3932 25998712 PMC4859809 · DOI
  9. [9]Visone R Croce CM MiRNAs and cancer Am J Pathol 174 1131 1138 2009 10.2353/ajpath.2009.080794 19264914 PMC2671346 · DOI
  10. [10]Croce CM Causes and consequences of microRNA dysregu lation in cancer Nat Rev Genet 10 704 714 2009 10.1038/nrg2634 19763153 PMC3467096 · DOI
  11. [11]Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Peterson A Noteboom J O'Briant KC Allen A Circulating microRNAs as stable blood based markers for cancer detection Proc Natl Acad Sci USA 105 10513 10518 2008 10.1073/pnas.0804549105 18663219 PMC2492472 · DOI · Paper page
  12. [12]Chen X Ba Y Ma L Cai X Yin Y Wang K Guo J Zhang Y Chen J Guo X Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases Cell Res 18 997 1006 2008 10.1038/cr.2008.282 18766170 · DOI · Paper page
  13. [13]Huang X Liang M Dittmar R Wang L Extracellular microRNAs in urologic malignancies: Chances and challenges Int J Mol Sci 14 14785 14799 2013 10.3390/ijms140714785 23863690 PMC3742273 · DOI
  14. [14]Izquierdo L Ingelmo Torres M Mallofré C Lozano JJ Verhasselt Crinquette M Leroy X Colin P Comperat E Roupret M Alcaraz A Mengual L Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma BJU Int 113 813 821 2014 10.1111/bju.12551 24180461 · DOI
  15. [15]Liu R Zhang C Hu Z Li G Wang C Yang C Huang D Chen X Zhang H Zhuang R A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis Eur J Cancer 47 784 791 2011 10.1016/j.ejca.2010.10.025 21112772 · DOI
  16. [16]Yu S Liu Y Wang J Guo Z Zhang Q Yu F Zhang Y Huang K Li Y Song E Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma J Clin Endocrinol Metab 97 2084 2092 2012 10.1210/jc.2011-3059 22472564 · DOI
  17. [17]Li LM Hu ZB Zhou ZX Chen X Liu FY Zhang JF Shen HB Zhang CY Zen K Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV positive hepatocarcinoma Cancer Res 70 9798 9807 2010 10.1158/0008-5472.CAN-10-1001 21098710 · DOI
  18. [18]Yang C Wang C Chen X Chen S Zhang Y Zhi F Wang J Li L Zhou X Li N Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas Int J Cancer 132 116 127 2013 10.1002/ijc.27657 22674182 · DOI
  19. [19]Sauter G Algaba F Amin M Tumours of the urinary system: Non-invasive urothelial neoplasia Eble JN Sauter G Epstein JI Sesterhenn IA The WHO Classification of Tumours of the Urinary System and Male Genital Organs IARC Press Lyon 110 114 2004
  20. [20]Sobin DH Witteking CH TNM Classification of Malignant Tumours 6th edition Wiley-Liss New York, NY 199 202 2002
  21. [21]Sanders I Holdenrieder S Walgenbach-Brunagel G Walgenbach-Brünagel G von Ruecker A Kristiansen G Müller SC Ellinger J Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma Int J Urol 19 1017 1025 2012 10.1111/j.1442-2042.2012.03082.x 22788411 · DOI
  22. [22]Cortez MA Bueso Ramos C Ferdin J Lopez-Berestein G Sood AK Calin GA MicroRNAs in body fluids-the mix of hormones and biomarkers Nat Rev Clin Oncol 8 467 477 2011 10.1038/nrclinonc.2011.76 21647195 PMC3423224 · DOI
  23. [23]Zen K Zhang CY Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers Med Res Rev 32 326 348 2012 10.1002/med.20215 22383180 · DOI
  24. [24]Brosnan JA Iacobuzio Donahue CA A new branch on the tree: Next-generation sequencing in the study of cancer evolution Semin Cell Dev Biol 23 237 242 2012 10.1016/j.semcdb.2011.12.008 22245832 PMC3314157 · DOI
  25. [25]Pritchard CC Cheng HH Tewari M MicroRNA profiling: Approaches and considerations Nat Rev Genet 13 358 369 2012 10.1038/nrg3198 22510765 PMC4517822 · DOI · Paper page
  26. [26]Mlcochova H Hezova R Stanik M Slaby O Urine microRNAs as potential noninvasive biomarkers in urologic cancers Urol Oncol 32 41 e41 e49 2014 10.1016/j.urolonc.2013.04.011 24035473 · DOI
  27. [27]Mengual L Lozano JJ Ingelmo-Torres M Gazquez C Ribal MJ Alcaraz A Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer Int J Cancer 133 2631 2641 2013 23686449
  28. [28]Adam L Wszolek MF Liu CG Jing W Diao L Zien A Zhang JD Jackson D Dinney CP Plasma microRNA profiles for bladder cancer detection Urol Oncol 31 1701 1708 2013 10.1016/j.urolonc.2012.06.010 22863868 PMC5226073 · DOI
  29. [29]Cookson VJ Bentley MA Hogan BV Horgan K Hayward BE Hazelwood LD Hughes TA Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours Cell Oncol (Dordr) 35 301 308 2012 10.1007/s13402-012-0089-1 22821209 PMC12995027 · DOI
  30. [30]Chung YW Bae HS Song JY Lee JK Lee NW Kim T Lee KW Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients Int J Gynecol Cancer 23 673 679 2013 10.1097/IGC.0b013e31828c166d 23542579 · DOI
  31. [31]Tanaka K Miyata H Yamasaki M Sugimura K Takahashi T Kurokawa Y Nakajima K Takiguchi S Mori M Doki Y Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer Ann Surg Oncol 20 Suppl 3 S607 S615 2013 10.1245/s10434-013-3093-4 23838916 · DOI
  32. [32]Wang HY Yan LX Shao Q Fu S Zhang ZC Ye W Zeng YX Shao JY Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing Clin Chem 60 773 782 2014 10.1373/clinchem.2013.214213 24563490 · DOI
  33. [33]Kannan M Mohan KV Kulkarni S Atreya C Membrane array-based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis Transfusion 49 1443 1450 2009 10.1111/j.1537-2995.2009.02140.x 19389023 · DOI
  34. [34]Zhang C Wang C Chen X Yang C Li K Wang J Dai J Hu Z Zhou X Chen L Expression profile of microRNAs in serum: A fingerprint for esophageal squamous cell carcinoma Clin Chem 56 1871 1879 2010 10.1373/clinchem.2010.147553 20943850 · DOI
  35. [35]Lionetti M Musto P Di Martino MT Fabris S Agnelli L Todoerti K Tuana G Mosca L Gallo Cantafio ME Grieco V Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia Clin Cancer Res 19 3130 3142 2013 10.1158/1078-0432.CCR-12-2043 23613318 · DOI
  36. [36]Kanaan Z Roberts H Eichenberger MR Billeter A Ocheretner G Pan J Rai SN Jorden J Williford A Galandiuk S A plasma microRNA panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer Ann Surg 258 400 408 2013 10.1097/SLA.0b013e3182a15bcc 24022433 · DOI
  37. [37]Zheng G Wang H Zhang X Yang Y Wang L Du L Li W Li J Qu A Liu Y Wang C Identification and validation of reference genes for qPCR detection of serum microRNAs in colorectal adenocarcinoma patients PLoS One 8 e83025 2013 10.1371/journal.pone.0083025 24349425 PMC3859607 · DOI
  38. [38]Wang Y Gu J Roth JA Hildebrandt MA Lippman SM Ye Y Minna JD Wu X Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer Cancer Res 73 4801 4809 2013 10.1158/0008-5472.CAN-12-3273 23774211 PMC3760306 · DOI
  39. [39]Liu C Iqbal J Teruya-Feldstein J Shen Y Dabrowska MJ Dybkaer K Lim MS Piva R Barreca A Pellegrino E MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma Blood 122 2083 2092 2013 10.1182/blood-2012-08-447375 23801630 PMC3778551 · DOI
  40. [40]Mahn R Heukamp LC Rogenhofer S von Ruecker A Müller SC Ellinger J Circulating microRNAs (miRNA) in serum of patients with prostate cancer Urology 77 1265 e9 e16 2011 10.1016/j.urology.2011.01.020 21539977 · DOI
  41. [41]Hauser S Wulfken LM Holdenrieder S Moritz R Ohlmann CH Jung V Becker F Herrmann E Walgenbach-Brünagel G von Ruecker A Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma Cancer Epidemiol 36 391 394 2012 10.1016/j.canep.2012.04.001 22542158 · DOI
  42. [42]Zhang Z Furge KA Yang XJ Teh BT Hansel DE Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder BMC Med Genomics 3 58 2010 10.1186/1755-8794-3-58 21159190 PMC3022544 · DOI
  43. [43]Tijsen AJ Creemers EE Moerland PD de Windt LJ van der Wal AC Kok WE Pinto YM MiR423-5p as a circulating biomarker for heart failure Circ Res 106 1035 1039 2010 10.1161/CIRCRESAHA.110.218297 20185794 · DOI
  44. [44]Xiao B Wang Y Li W Baker M Guo J Corbet K Tsalik EL Li QJ Palmer SM Woods CW Plasma microRNA signature as a noninvasive biomarker for acute graft versus host disease Blood 122 3365 3375 2013 10.1182/blood-2013-06-510586 24041574 PMC3821726 · DOI
  45. [45]Hui AB Lenarduzzi M Krushel T Waldron L Pintilie M Shi W Perez-Ordonez B Jurisica I O'Sullivan B Waldron J Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas Clin Cancer Res 16 1129 1139 2010 10.1158/1078-0432.CCR-09-2166 20145181 · DOI
  46. [46]Farazi TA Horlings HM Ten Hoeve JJ Mihailovic A Halfwerk H Morozov P Brown M Hafner M Reyal F van Kouwenhove M MicroRNA sequence and expression analysis in breast tumors by deep sequencing Cancer Res 71 4443 4453 2011 10.1158/0008-5472.CAN-11-0608 21586611 PMC3129492 · DOI
  47. [47]Yang H Cho ME Li TW Peng H Ko KS Mato JM Lu SC MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma J Clin Invest 123 285 298 2013 10.1172/JCI63861 23241961 PMC3533284 · DOI
  48. [48]Fromont G Rouprêt M Amira N Sibony M Vallancien G Validire P Cussenot O Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma Eur Urol 48 764 770 2005 10.1016/j.eururo.2005.07.005 16126329 · DOI
  49. [49]Nakanishi K Kawai T Hiroi S Kumaki F Torikata C Aurues T Ikeda T Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract Cancer 86 2109 2116 1999 10.1002/(SICI)1097-0142(19991115)86:10<2109::AID-CNCR32>3.0.CO;2-6 10570439 · DOI
  50. [50]Nakanishi K Hiroi S Tominaga S Aida S Kasamatsu H Matsuyama S Matsuyama T Kawai T Expression of hypoxia inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract Clin Cancer Res 11 2583 2590 2005 10.1158/1078-0432.CCR-04-1685 15814637 · DOI

Cited by

Sorted by citations

Authors
TAO, J., YANG, X., LI, P., WEI, J., DENG, X., CHENG, Y., QIN, C., JU, X., MENG, X., LI, J., GU, M., LU, Q., & YIN, C.
Affiliations
Jiangsu Province Hospital (CN)
Corresponding author
GU, MIN
ORCID
Venue
Molecular Medicine Reports
Publisher
Spandidos Publications
Published
2015-08-27
Volume
12
Issue
5
Pages
6752-6760
ISSN
  • 1791-2997 (ISSN-L)
  • 1791-3004
DOI
10.3892/mmr.2015.4257
PMC
PMC4626156
OpenAlex
W1932529623
Cited by
29
References
0
Citations by year
2026: 4 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 1
FWCI
0.77
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Molecular Medicine Reports (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81272832, BK2011848, BL2012027, 2011-WS-121, 81201997)
  • Government of Jiangsu Province
  • Natural Science Foundation of Jiangsu Province (81272832, BK2011848, 2011-WS-121, 81201997)
  • Nanjing Medical University
  • Priority Academic Program Development of Jiangsu Higher Education Institutions (81272832, 81201997, BK2011848)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Keywords
upper tract urothelial carcinoma, circulating microRNAs, tumor markers, diagnostic biomarkers, miR-431-5p, miR-423-5p, miR-191-5p, miR-26a-5p, miR-22-3p, miR-16-5p, hematuria, non-invasive cancer detection
MeSH terms
Aged, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, ROC Curve, Biomarkers, Tumor, Cluster Analysis, Case-Control Studies, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review